Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 2 (February)

1. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.
   Science, 319(5863): 627-30. [Abstract] [Full-text]
2. Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.
   J Am Coll Cardiol, 51(5): 546-51. [Abstract] [Full-text]
3. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.
   Eur J Vasc Endovasc Surg, 35(2): 238-45. [Abstract] [Full-text]
4. Carbamate-linked cationic lipids for gene delivery.
   Bioorg Med Chem, 16(2): 995-1005. [Abstract] [Full-text]
5. Effect of pharmacists on medication errors in an emergency department.
   Am J Health Syst Pharm, 65(4): 330-3. [Abstract] [Full-text]
6. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets.
   Bioinformatics, 24(3): 389-95. [Abstract] [Full-text]
7. Ligand based dendritic systems for tumor targeting.
   Int J Pharm, 350(1): 3-13. [Abstract] [Full-text]
8. How to achieve sustained and complete protein release from PLGA-based microparticles?
   Int J Pharm, 350(1): 14-26. [Abstract] [Full-text]
9. High throughput methods to characterize protein permeation and release.
   Int J Pharm, 350(1): 272-8. [Abstract] [Full-text]
10. Floating dosage forms to prolong gastro-retention--the characterisation of calcium alginate beads.
    Int J Pharm, 350(1): 301-11. [Abstract] [Full-text]
11. Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system.
    Int J Pharm, 350(1): 247-56. [Abstract] [Full-text]
12. Self-assembled drug delivery systems 2. Cholesteryl derivatives of antiviral nucleoside analogues: synthesis, properties and the vesicle formation.
    Int J Pharm, 350(1): 330-7. [Abstract] [Full-text]
13. A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine.
    Int J Pharm, 350(1): 27-34. [Abstract] [Full-text]
14. Prescription privileges for psychologists: opinions of pediatric psychologists and pediatricians.
    J Pediatr Psychol, 33(2): 176-84. [Abstract] [Full-text]
15. Ensuring appropriate timing of antimicrobial prophylaxis.
    J Bone Joint Surg Am, 90(2): 226-32. [Abstract] [Full-text]
16. Preparing for pediatric emergencies: drugs to consider.
    Pediatrics, 121(2): 433-43. [Abstract] [Full-text]
17. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
    Cancer Res, 68(3): 843-51. [Abstract] [Full-text]
18. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery.
    J Thorac Cardiovasc Surg, 135(2): 405-11. [Abstract] [Full-text]
19. Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients.
    Am J Infect Control, 36(1): 54-8. [Abstract] [Full-text]
20. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
    Future Oncol, 4(1): 41-50. [Abstract] [Full-text]
21. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Gynecol Oncol, 108(2): 276-81. [Abstract] [Full-text]
22. Antiproliferative effects of the major tea polyphenol, (-)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma.
    Gynecol Oncol, 108(2): 326-31. [Abstract] [Full-text]
23. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
    Gynecol Oncol, 108(2): 336-41. [Abstract] [Full-text]
24. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
    Gynecol Oncol, 108(2): 342-7. [Abstract] [Full-text]
25. Effect of board certification on antihypertensive treatment intensification in patients with diabetes mellitus.
    Circulation, 117(5): 623-8. [Abstract] [Full-text]
26. In vitro analysis of the TAT protein transduction domain as a drug delivery vehicle in protozoan parasites.
    Exp Parasitol, 118(3): 303-7. [Abstract] [Full-text]
27. Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics.
    J Community Health, 33(2): 69-77. [Abstract] [Full-text]
28. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    J Natl Cancer Inst, 100(3): 207-12. [Abstract] [Full-text]
29. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
    Br J Cancer, 98(3): 558-63. [Abstract] [Full-text]
30. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group.
    Br J Cancer, 98(3): 542-6. [Abstract] [Full-text]
31. Gingival and bone necrosis caused by accidental sodium hypochlorite injection instead of anaesthetic solution.
    Int Endod J, 41(3): 267-70. [Abstract] [Full-text]
32. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
    J Clin Oncol, 26(5): 778-85. [Abstract] [Full-text]
33. Adjuvant corticosteroid therapy for chronic disseminated candidiasis.
    Clin Infect Dis, 46(5): 696-702. [Abstract] [Full-text]
34. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.
    Clin Infect Dis, 46(5): 719-25. [Abstract] [Full-text]
35. Clinical and histopathological features and a unique spectrum of organisms significantly associated with chronic granulomatous disease osteomyelitis during childhood.
    Clin Infect Dis, 46(5): 745-9. [Abstract] [Full-text]
36. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
    Clin Infect Dis, 46(5): 732-40. [Abstract] [Full-text]
37. Modeling recombinant immunotoxin efficacies in solid tumors.
    Ann Biomed Eng, 36(3): 486-512. [Abstract] [Full-text]
38. Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05.
    Drug Alcohol Rev, 27(2): 160-4. [Abstract] [Full-text]
39. The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia.
    Drug Alcohol Rev, 27(2): 145-51. [Abstract] [Full-text]
40. Chemical imaging of drug eluting coatings: combining surface analysis and confocal Raman microscopy.
    J Control Release, 126(2): 111-21. [Abstract] [Full-text]
41. Charged nanoparticles delivery to the eye using hydrogel iontophoresis.
    J Control Release, 126(2): 156-61. [Abstract] [Full-text]
42. Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures.
    J Control Release, 126(2): 139-48. [Abstract] [Full-text]
43. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin.
    Biomaterials, 29(11): 1664-75. [Abstract] [Full-text]
44. Drug release from ion-exchange microspheres: mathematical modeling and experimental verification.
    Biomaterials, 29(11): 1654-63. [Abstract] [Full-text]
45. Restrictive access to clopidogrel and mortality following coronary stent implantation.
    CMAJ, 178(4): 413-20. [Abstract] [Full-text]
46. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.
    CMAJ, 178(4): 405-9. [Abstract] [Full-text]
47. Compensatory nicotine self-administration in rats during reduced access to nicotine: an animal model of smoking reduction.
    Exp Clin Psychopharmacol, 16(1): 86-97. [Abstract] [Full-text]
48. Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer.
    Expert Opin Ther Targets, 12(3): 367-76. [Abstract] [Full-text]
49. Targeting signaling pathways in ovarian cancer.
    Expert Opin Ther Targets, 12(3): 353-65. [Abstract] [Full-text]
50. CD70 as a therapeutic target in human malignancies.
    Expert Opin Ther Targets, 12(3): 341-51. [Abstract] [Full-text]
51. Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?
    Expert Opin Ther Targets, 12(3): 327-39. [Abstract] [Full-text]
52. CD4+ CD25+ regulatory T cells: a therapeutic target for liver diseases.
    Expert Opin Ther Targets, 12(3): 313-26. [Abstract] [Full-text]
53. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.
    Expert Opin Ther Targets, 12(3): 301-12. [Abstract] [Full-text]
54. Cysteine cathepsin S as an immunomodulatory target: present and future trends.
    Expert Opin Ther Targets, 12(3): 291-9. [Abstract] [Full-text]
55. Intracellular immune dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: state of the art and therapeutic implications.
    Expert Opin Ther Targets, 12(3): 281-9. [Abstract] [Full-text]
56. Anti-infectives targeting the isoprenoid pathway of Toxoplasma gondii.
    Expert Opin Ther Targets, 12(3): 253-63. [Abstract] [Full-text]
57. Pulse pressure variation and stroke volume variation during different loading conditions in a paediatric animal model.
    Acta Anaesthesiol Scand, 52(3): 374-80. [Abstract] [Full-text]
58. Adapting proteostasis for disease intervention.
    Science, 319(5865): 916-9. [Abstract] [Full-text]
59. Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure.
    Fertil Steril, 89(2): 342-7. [Abstract] [Full-text]
60. Estro-progestin supplementation enhances the growth hormone secretory responsiveness to ghrelin infusion in postmenopausal women.
    Fertil Steril, 89(2): 398-403. [Abstract] [Full-text]
61. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
    Rheumatology (Oxford), 47(3): 334-8. [Abstract] [Full-text]
62. Medication errors involving patient-controlled analgesia.
    Am J Health Syst Pharm, 65(5): 429-40. [Abstract] [Full-text]
63. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    J Clin Oncol, 26(6): 925-33. [Abstract] [Full-text]
64. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
    J Clin Oncol, 26(6): 870-6. [Abstract] [Full-text]
65. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    J Clin Oncol, 26(6): 863-9. [Abstract] [Full-text]
66. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
    J Clin Oncol, 26(6): 848-55. [Abstract] [Full-text]
67. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.
    Lancet, 371(9612): 559-68. [Abstract] [Full-text]
68. Prophylactic antibiotics and surgery for primary clefts.
    Br J Oral Maxillofac Surg, 46(2): 107-9. [Abstract] [Full-text]
69. Routine antibiotic prophylaxis is not necessary during operations to remove third molars.
    Br J Oral Maxillofac Surg, 46(2): 133-5. [Abstract] [Full-text]
70. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Cancer Res, 68(4): 1154-61. [Abstract] [Full-text]
71. Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial.
    J Am Acad Dermatol, 58(3): 387-94. [Abstract] [Full-text]
72. Patients' beliefs and preferences regarding doctors' medication recommendations.
    J Gen Intern Med, 23(3): 236-41. [Abstract] [Full-text]
73. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation.
    Clin Immunol, 126(3): 315-21. [Abstract] [Full-text]
74. Predicting the interactome of Xanthomonas oryzae pathovar oryzae for target selection and DB service.
    BMC Bioinformatics, 9: 41. [Abstract] [Full-text]
75. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls.
    Am J Ophthalmol, 145(3): 518-526. [Abstract] [Full-text]
76. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy.
    JAMA, 299(7): 769-77. [Abstract] [Full-text]
77. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
    J Natl Cancer Inst, 100(4): 261-9. [Abstract] [Full-text]
78. Drug-drug interaction programs in clinical practice.
    Clin Pharmacol Ther, 83(3): 396-8. [Abstract] [Full-text]
79. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
    Circulation, 117(7): 886-96. [Abstract] [Full-text]
80. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
    Clin Pharmacol Ther, 83(3): 460-70. [Abstract] [Full-text]
81. Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment.
    Clin Pharmacol Ther, 83(3): 401-12. [Abstract] [Full-text]
82. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women.
    Clin Pharmacol Ther, 83(3): 422-9. [Abstract] [Full-text]
83. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
    Clin Pharmacol Ther, 83(3): 413-5. [Abstract] [Full-text]
84. From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia.
    Malar J, 7: 25. [Abstract] [Full-text]
85. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Eur J Haematol, 80(3): 227-35. [Abstract] [Full-text]
86. Leprosy reversal reaction as immune reconstitution inflammatory syndrome in patients with AIDS.
    Clin Infect Dis, 46(6): e56-60. [Abstract] [Full-text]
87. The effects of prehydration on the properties of cerebrospinal fluid and the spread of isobaric spinal anesthetic drug.
    Anesth Analg, 106(3): 1002-7, table of contents. [Abstract] [Full-text]
88. Antidepressant prescribing and changes in antidepressant poisoning mortality and suicide in England, 1993-2004.
    J Public Health (Oxf), 30(1): 60-8. [Abstract] [Full-text]
89. The response to IV rt-PA in very old stroke patients.
    Eur J Neurol, 15(3): 253-6. [Abstract] [Full-text]
90. Electrosonic ejector microarray for drug and gene delivery.
    Biomed Microdevices, 10(2): 299-308. [Abstract] [Full-text]
91. 188Re-labeled MPEG-modified superparamagnetic nanogels: preparation and targeting application in rabbits.
    Biomed Microdevices, 10(2): 281-7. [Abstract] [Full-text]
92. Alginate and chitosan particles as drug delivery system for cell therapy.
    Biomed Microdevices, 10(2): 131-40. [Abstract] [Full-text]
93. Noninvasive, medical management for non-ST-elevation acute coronary syndromes.
    Am Heart J, 155(3): 397-407. [Abstract] [Full-text]
94. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals.
    J Infect, 56(3): 219-25. [Abstract] [Full-text]
95. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Jpn J Clin Oncol, 38(2): 99-105. [Abstract] [Full-text]
96. The impact of clinical pharmacists on drug-related problems and clinical outcomes.
    Basic Clin Pharmacol Toxicol, 102(3): 275-80. [Abstract] [Full-text]
97. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1.
    Gynecol Oncol, 108(3): 609-18. [Abstract] [Full-text]
98. Hormone replacement therapy and ovarian cancer risk: a meta-analysis.
    Gynecol Oncol, 108(3): 641-51. [Abstract] [Full-text]
99. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.
    Gynecol Oncol, 108(3): 493-9. [Abstract] [Full-text]
100. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
     Gynecol Oncol, 108(3): 500-4. [Abstract] [Full-text]
101. Identification and design of peptides as a new drug delivery system for the brain.
     J Pharmacol Exp Ther, 324(3): 1064-72. [Abstract] [Full-text]
102. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
     Gynecol Oncol, 108(3): 510-4. [Abstract] [Full-text]
103. Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers.
     J Pharmacol Exp Ther, 324(3): 902-10. [Abstract] [Full-text]
104. Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study.
     Atherosclerosis, 197(1): 443-7. [Abstract] [Full-text]
105. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
     Leuk Lymphoma, 49(3): 524-30. [Abstract] [Full-text]
106. Clinical outcome of children with newly diagnosed acute lymphoblastic leukemia treated in a single center in Shanghai, China.
     Leuk Lymphoma, 49(3): 488-94. [Abstract] [Full-text]
107. Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab.
     Leuk Lymphoma, 49(3): 462-9. [Abstract] [Full-text]
108. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.
     Leuk Lymphoma, 49(3): 447-50. [Abstract] [Full-text]
109. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
     Pediatr Blood Cancer, 50(4): 739-45. [Abstract] [Full-text]
110. Human uridine-cytidine kinase phosphorylation of ribavirin: a convenient method for activation of ribavirin for conjugation to proteins.
     J Biomed Sci, 15(2): 205-13. [Abstract] [Full-text]
111. Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years.
     Pediatr Blood Cancer, 50(4): 784-7. [Abstract] [Full-text]
112. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: Radiotherapy dose adaptation after chemotherapy response to minimize late effects.
     Pediatr Blood Cancer, 50(4): 849-53. [Abstract] [Full-text]
113. Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
     Pediatr Blood Cancer, 50(4): 757-60. [Abstract] [Full-text]
114. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
     Pediatr Blood Cancer, 50(4): 883-5. [Abstract] [Full-text]
115. Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer.
     Int J Cancer, 122(8): 1716-21. [Abstract] [Full-text]
116. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial.
     Int J Cancer, 122(8): 1690-4. [Abstract] [Full-text]
117. Mismatch repair expression in testicular cancer predicts recurrence and survival.
     Int J Cancer, 122(8): 1774-7. [Abstract] [Full-text]
118. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction.
     Circulation, 117(8): 1028-36. [Abstract] [Full-text]
119. MRI detection of early blood-brain barrier disruption: parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis.
     Stroke, 39(3): 1025-8. [Abstract] [Full-text]
120. Effective and safe conditions of low-frequency transcranial ultrasonic thrombolysis for acute ischemic stroke: neurologic and histologic evaluation in a rat middle cerebral artery stroke model.
     Stroke, 39(3): 1007-11. [Abstract] [Full-text]
121. Effects of resuscitation fluid on neurologic physiology after cerebral trauma and hemorrhage.
     J Trauma, 64(2): 348-57. [Abstract] [Full-text]
122. Secondary abdominal compartment syndrome after severe extremity injury: are early, aggressive fluid resuscitation strategies to blame?
     J Trauma, 64(2): 280-5. [Abstract] [Full-text]
123. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
     Br J Ophthalmol, 92(3): 356-60. [Abstract] [Full-text]
124. Pharmaconutrition: a new emerging paradigm.
     Curr Opin Gastroenterol, 24(2): 215-22. [Abstract] [Full-text]
125. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
     Ann Oncol, 19(3): 538-44. [Abstract] [Full-text]
126. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.
     Ann Oncol, 19(3): 560-5. [Abstract] [Full-text]
127. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
     Ann Oncol, 19(3): 553-9. [Abstract] [Full-text]
128. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
     Ann Oncol, 19(3): 545-52. [Abstract] [Full-text]
129. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
     Ann Oncol, 19(3): 520-6. [Abstract] [Full-text]
130. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
     Ann Oncol, 19(3): 448-53. [Abstract] [Full-text]
131. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.
     Ann Oncol, 19(3): 465-72. [Abstract] [Full-text]
132. Identifying how age and gender influence prescription drug use in a primary health care environment in Catalonia, Spain.
     Br J Clin Pharmacol, 65(3): 407-17. [Abstract] [Full-text]
133. Current management and challenges of malignant disease in the CNS in paediatric leukaemia.
     Lancet Oncol, 9(3): 257-68. [Abstract] [Full-text]
134. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
     Lancet Oncol, 9(3): 247-56. [Abstract] [Full-text]
135. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies.
     Hum Reprod, 23(3): 674-8. [Abstract] [Full-text]
136. Effect of preoperative use of propranolol on postoperative outcome in patients with tetralogy of Fallot.
     Am J Cardiol, 101(5): 693-5. [Abstract] [Full-text]
137. Management of metastatic prostate cancer: the crucial role of geriatric assessment.
     BJU Int, 101: 23-9. [Abstract] [Full-text]
138. Chemotherapy in hormone-refractory prostate cancer.
     BJU Int, 101: 11-5. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.